# Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921

> **NCT03298061** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 100 (actual)

## Conditions studied

- Churg-Strauss Syndrome
- Eosinophilic Granulomatosis With Polyangiitis

## Interventions

- **DRUG:** Mepolizumab
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT03298061
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-14
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-02-16
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298061, "Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03298061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*